Clinical Trial Update: A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas [Phase 1]

View source ↗

Summary

A Phase 1 dose-finding study of ASP2802 in CD20-positive B-cell lymphomas was conducted, but the study has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma

Drugs mentioned

• ASP2802

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: B-cell Lymphoma | Phase 1 | Status: TERMINATED